SEC Comment Letter 0000000000-23-010557 to ProMIS Neurosciences Inc. (PMN)

ProMIS Neurosciences Inc.
Date: Sept. 25, 2023 · CIK: 0001374339 · Accession: 0000000000-23-010557

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-274656

Date

September 25, 2023

Author

Gail Farfel, Ph.D.

Form

UPLOAD

Company

ProMIS Neurosciences Inc.

Letter

United States securities and exchange commission logo September 25, 2023 Gail Farfel, Ph.D. Chief Executive Officer ProMIS Neurosciences Inc. Suite 200, 1920 Yonge Street Toronto, Ontario M4S 3E2 Re:ProMIS Neurosciences Inc. Registration Statement on Form S-3 Filed September 22, 2023 File No. 333-274656 Dear Gail Farfel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Nicole Daley, Esq.

Show Raw Text

United States securities and exchange commission logo
September 25, 2023
Gail Farfel, Ph.D.
Chief Executive Officer
ProMIS Neurosciences Inc.
Suite 200, 1920 Yonge Street
Toronto, Ontario
M4S 3E2
Re:ProMIS Neurosciences Inc.
Registration Statement on Form S-3
Filed September 22, 2023
File No. 333-274656
Dear Gail Farfel:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Nicole Daley, Esq.

SecProbe.io